A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in one budget line immediately. Read against their own published guidance, none of the region's six major payer systems operates a method that can value that trade. This story works through each rulebook in turn and asks what would have to change in the method, not in the politics, for prevention to become fundable.

METHOD IN BRIEF

Each payer system in this story is described from its agency's own published guidance and official materials, cited in the sources note. The same question is asked of each: what in the published method could receive a multi-condition prevention filing?

Where the story states that a method contains no provision, that statement rests on the documented absence of such provision from the cited guidance, not on inference from behaviour or on unnamed sources.

No payer system is scored or ranked, and no market is benchmarked; regional benchmarking is the province of the APAC Bioeconomy Index. Facts verified to 4 September 2026.

THE ARITHMETIC NOBODY OWNS

Begin with a product that does not exist and an invoice that would. Suppose a gerotherapeutic clears the gauntlet this series has spent eight stories walking: it finds a registrable endpoint, survives decades of exposure in a well population, holds a cost of goods that population can bear, and demonstrates in a completed outcomes trial that it delays the onset of five age-associated conditions, say type 2 diabetes, heart failure, chronic kidney disease, osteoporotic fracture and dementia, by roughly three years each.

Where does the value land? In the diabetes budget, some years from now. In the cardiology budget, later. In the dialysis budget, later still. In long-term care insurance, which in Japan and Korea is a separate statutory scheme with its own premiums and its own actuaries, one or two decades out. In the pension system, ambiguously, because people who stay well longer also draw longer. The savings are real, but they are scattered across five or six ledgers, none of which belongs to the official who must approve the price, and they mature on a schedule measured in decades, which is to say several electoral cycles and many closed budget years after the decision has to be made.

Where does the cost land? In one place, immediately: the drug budget of whichever payer lists the product, in the first fiscal year, multiplied by an eligible population that is by definition enormous, because the product treats people who are not yet sick.

Every health technology assessment system is, at bottom, a machine for comparing those two quantities. The finding of this story is that no machine in the region is built to run this particular comparison. That is not asserted as an attitude. It is documented, system by system, from each agency's own published guidance, by asking the same question six times: if a multi-condition prevention filing arrived tomorrow, what in the method could receive it?

Four things, specifically, would need to be there. A time horizon that credits benefit arriving decades out at something close to face value. A rule for aggregating value across several prevented conditions into one filing. A comparator convention for a product that has no predecessor. And a payment instrument that spreads the cost across the years in which the benefit matures, rather than dropping it whole into the launch-year budget impact table. Hold those four requirements steady, and read.

One more thing before the rulebooks, on why this question is urgent now rather than eventually. Earlier stories in this series established that the region can plausibly make such a product: the endpoints are being written here, the manufacturing base is here, and the cost floor for long-horizon preventive medication has already been set here by the incretin class. The remaining question was always the last one: who signs. And the timing is not neutral. Super-aged systems are, by construction, already financing the consequences of aging at scale, through hospital budgets, long-term care schemes and pension outlays that grow every year without a decision being taken. The same demographic pressure that creates the demand for deferral is the pressure that consumes the fiscal room in which deferral could be bought. Waiting does not make this easier. Every year of waiting makes the annual budget tighter and the case for long-horizon spending politically weaker, which is precisely why the fix argued for here is located in method, where a committee can act, rather than in budgets, where nobody can.

JAPAN: THE PRICE IS ADJUSTED, THE QUESTION IS NEVER ASKED

Japan runs the most formalised cost-effectiveness machinery in the region, and it is the clearest illustration of the gap, because the machinery exists to answer a different question. Cost-effectiveness evaluation was piloted from fiscal 2016 and formally incorporated into the pricing system in April 2019, administered by the Central Social Insurance Medical Council, Chuikyo, with technical review by the Center for Outcomes Research and Economic Evaluation for Health, C2H. Products are selected principally when expected peak annual sales reach ten billion yen, with some selected at five billion. The company submits its analysis within nine months, an academic group reanalyses, and the whole cycle runs fifteen to eighteen months.

Three structural facts follow from the published framework. First, selection is triggered by sales size. The system notices a product when it threatens the budget, not when its value profile is unusual. Second, the evaluation's output is a price adjustment, not a coverage decision. C2H's own materials state that results are used for adjusting the premium and profit-rate portions of a price already set by listing rules, with the reference value at five million yen per quality-adjusted life year, stepwise bands at 7.5 and 10 million, a higher reference for special categories, and reductions capped at roughly ten to fifteen percent of the pre-adjustment price. Coverage itself is decided upstream, by comparator-based listing rules the evaluation never touches.

Third, and decisive for prevention: Japan has already met the multi-indication problem, and solved it in the wrong direction. Because one product carries exactly one price, products with several indications had their incremental cost-effectiveness ratios combined as a weighted mean during the pilot, a method Chuikyo itself found difficult to interpret and has continued to debate. Read that again from the perspective of a prevention filing. The arithmetic for handling several value streams at once exists inside the system. It points toward averaging them into a single adjustable number, not toward adding them so that a claim spanning five disease areas could be valued as the sum of its deferrals. And nothing in the public framework describes any provision for crediting, inside a drug price, spending averted in the separate long-term care insurance scheme, which is where much of a gerotherapeutic's value would surface. The question a prevention filing needs answered is not answered badly in Japan. It is not asked.

KOREA: THE LIST, THE THRESHOLD AND THE CAP

Korea's positive list system, in force since December 2006, makes cost-effectiveness a condition of entry rather than a post-hoc price lever. The Health Insurance Review and Assessment Service reviews submissions, its benefit coverage advisory committee recommends, and the insurer negotiates price. No official cost-per-QALY threshold has ever been published, but the deliberative record and the academic literature describe a working reference of roughly one gross domestic product per capita per QALY for general conditions, with something nearer twice that entertained for severe disease.

Notice the direction of every flexibility the system has added since. Risk-sharing agreements, available since 2013 and predominantly financial in structure, simple refunds and expenditure caps, cluster in oncology. The pharmacoeconomic evaluation exemption, introduced in 2015, waives the cost-effectiveness demonstration entirely, but only for treatments of rare or severe conditions with no alternative and a small population, priced by reference to seven benchmark countries. The threshold ladder climbs with severity and rarity. A gerotherapeutic sits at the exact opposite corner of that map: the population is the largest imaginable, no one in it is severely ill, and the condition addressed is not, in Korea or anywhere else in the region, a disease at all. Every published relaxation in the Korean method is scoped so that a prevention filing cannot reach it, and the instruments that do exist for managing budget exposure, refunds and annual caps, are built to limit this year's spend, not to spread this year's spend against savings that mature in the 2040s. The guidance evaluates a drug against the alternatives for the indication applied for. A filing whose claim runs across five ICD chapters has no described route in.

TAIWAN: THE BUDGET THAT MUST BALANCE THIS YEAR

Taiwan's single-payer National Health Insurance has operated on a global budget since the early 2000s, growing, in the administration's own description, by around three to five percent a year. New drug submissions receive a health technology assessment report from the Center for Drug Evaluation within 42 calendar days, covering comparative effectiveness, economics and budget impact, and then proceed to the joint committee of the Pharmaceutical Benefit and Reimbursement Scheme. The documented experience of that pathway is not fast: a study of the second-generation system found an average of 436 days from submission to effective reimbursement, and 742 for oncology drugs. Price-volume agreements engage when forecast sales exceed two hundred million New Taiwan dollars in any of the first five listed years.

A global budget is the purest expression of this story's problem. It is an instrument for making the current year close, and it is very good at that. Money for a preventive product must come out of the same envelope currently treating the people who are already sick, this year, and the mechanism that would eventually repay the envelope, lower utilisation among people who did not get sick in the 2040s, has no representation anywhere in the ledger. Taiwan has, to its credit, modernised its contracting: a September 2018 amendment to the reimbursement scheme introduced managed entry agreements in which manufacturers refund against results, and the endpoints those agreements are keyed to are named in the announcement: overall survival, disease-free survival, clinical response. Every one of them is a disease endpoint measured in a sick patient. An agreement keyed to the continued non-occurrence of disease in a well population is not among the described instruments, and inside a budget that must balance annually it is hard to see where such an agreement would put its money.

SINGAPORE: THE HORIZON THAT GETS SHORTENED

Singapore's Agency for Care Effectiveness, established by the Ministry of Health in 2015, evaluates drugs and vaccines to inform national subsidy decisions, working to its published Drug and Vaccine Evaluation Methods and Process Guide, now in version 3.1. Evaluations run at two depths, expedited or full, with the level set by estimated budget impact and by uncertainty around clinical and cost parameters; full evaluations take six to nine months and pair with value-based price negotiation.

For this story, the most instructive public document is not the guide but the record of how it is applied. A 2024 review of the first six company-led submissions found that four of the six were judged not cost-effective after the agency's revisions to the submitted models, and the named revisions included shortening the time horizon and applying treatment waning. Understand this correctly: that is disciplined assessment practice, and given immature survival data it is defensible case by case. But it documents the standing reflex of the method, which is that when evidence is uncertain, the horizon contracts. A gerotherapeutic's entire value proposition lives in the far end of the model, in years twenty through forty, precisely the region of the projection an assessor truncates first, and its evidence at filing will by construction be uncertain, because nobody runs a forty-year trial. The reflex that protects the fund from optimistic oncology extrapolation is the same reflex that makes deferral unvaluable. The sharpening irony is that Singapore is the region's most committed preventive-policy state, willing to fund prevention at scale when it arrives as a programme, through policy decision. When prevention arrives instead as a molecule with a price, it must pass through a method whose documented practice is to discount and shorten exactly what the molecule is selling.

AUSTRALIA: FIVE PERCENT, COMPOUNDED AGAINST PREVENTION

Australia deserves a kind of respect here, because it is the only system in the region that writes its prevention penalty down as a number. The Pharmaceutical Benefits Advisory Committee's guidelines set a base-case discount rate of five percent a year on both costs and health outcomes, a figure adopted around 1990 and unchanged since. The arithmetic is unforgiving. At five percent, a health benefit delivered thirty years from now enters the model at about 23 cents on the dollar. At 3.5 percent it would enter at about 36. At the 1.5 percent used in Canada and England it would enter at about 64. The same trial result, the same deferral of the same diseases, is worth almost three times more to a Canadian committee than to an Australian one before a single clinical fact has been disputed.

This is not an obscure technicality and Australia has not treated it as one. A formal review of the discount rate ran through 2022, prompted by the strategic agreement with industry, and drew submissions arguing that the five percent rate had delayed listings of exactly the long-horizon interventions this story is about, with human papillomavirus and meningococcal vaccines cited among the examples. The committee's published advice was that the rate should be no lower than 3.5 to four percent, and that even this change should follow a broader whole-of-government policy decision on discounting health interventions, made in light of the wider health technology assessment review. That is the most honest sentence any regional payer has produced on this subject, and it is worth restating in plain terms: the committee acknowledged the case for change, quantified the defensible landing zone, and located the decision above its own pay grade. The base case stood at five percent as this story went to press. A gerotherapeutic filing in Australia today would be assessed under the most transparently prevention-hostile parameter in the region, published in the open, with the fix already scoped and waiting on a decision that belongs to no one in particular. The theme of this story, in one country.

CHINA: THE ANNUAL NEGOTIATION, AND A SECOND DOOR

China's two dominant payer instruments are the shortest-horizon in the region. Volume-based procurement, now past its eleventh national round, clears off-patent molecules at commodity prices. The National Reimbursement Drug List negotiation admits innovation through an annual cycle of steep confidential price cuts; in the round concluded for the 2025 list, 117 drugs were negotiated, 89 entered, and the average reduction reported was 63 percent. Listed prices then face renewal within one to two years. Whatever else can be said about this machinery, it re-prices faster than any prevention benefit could possibly report. A product whose value emerges over twenty years, negotiated annually by an agency whose founding mandate is spending discipline, will be re-priced twenty times before its first claim can be checked.

Then, in December 2025, something structurally new. Alongside the annual list update, the National Healthcare Security Administration released the first Commercial Health Insurance Innovative Drug List, nineteen high-cost drugs across cancer, Alzheimer's disease and rare conditions, effective 1 January 2026, formulated by the administration but with commercial insurance experts holding significant say over inclusion and price. Nothing about the list is prevention-specific, and its first cohort is conventional high-cost therapy. But it is the first time a major payer in this region has built formal state scaffolding around the admission that the basic scheme cannot absorb every valuable product, and has constructed a routing mechanism toward balance sheets that can. File that fact; the last sections of this story depend on it.

THE COMPARATOR PROBLEM

Underneath all six systems sits a shared assumption worth surfacing on its own, because a gerotherapeutic breaks it before any spreadsheet opens. Every method in this story begins with a comparator. Japan's listing prices are formed by similar-efficacy comparison. Korea prices against the weighted average of alternatives. Taiwan leans on reference pricing. Singapore models against local standard of care. The PBAC assesses against the therapy most likely to be replaced. The comparator does two jobs at once: it is the clinical anchor that defines incremental benefit, and it is the price anchor that defines what the system was already willing to pay.

A gerotherapeutic has neither. The therapy most likely to be replaced is nothing, five times over. Incremental cost against no treatment is the entire price of the product, which guarantees the worst possible arithmetic at the first gate. And there is no prior product anywhere in the world from which to import a price, because no other jurisdiction has solved this first. Korea's exemption track proves that comparator-free listing is administrable when the state decides it should be, but the track works by borrowing a price from seven reference countries, and a first-in-category prevention product would arrive with no foreign price to borrow. The comparator requirement looks like a technical preliminary. For this category it is a locked front door.

THE PRIVATE ROUTE

Now ask who actually holds the exposure. The entities whose liabilities genuinely shorten when morbidity compresses are not ministries of health, which budget one year at a time. A life and health insurer carrying twenty-year critical illness and hospitalisation books gains directly and calculably when onset defers by three years. A pension and annuity writer holds the opposite side of the same risk and prices longevity every day. Large self-insuring employers carry medical costs and lose output to the caregiving of employees' parents. These balance sheets already operate on thirty to sixty year horizons, already employ actuaries whose entire discipline is valuing distant contingent events, and are not subject to annual appropriation or electoral cycles. In other words, the four things a prevention filing needs, a long horizon, cross-condition aggregation, tolerance for a product with no predecessor, and multi-year payment structures, are not exotic to insurance. They are approximately a description of insurance.

The region's insurers already pay for prevention in a primitive form, through wellness programmes that adjust premiums against verified behaviour. The step from crediting gym attendance to crediting a pharmacological deferral verified against claims data is a product-design and evidence problem, not a philosophical one, and the claims data to verify it sits inside the insurer already. Korea's risk-sharing machinery shows that payers in this region can write and administer conditional contracts. Taiwan's 2018 amendment shows that outcome-keyed refunds are workable. China has now built the first state-sponsored routing channel from the public list to commercial balance sheets. What no one has yet written is the instrument that combines them at a prevention horizon: an amortised, outcomes-contingent subscription in which an insurer pays annually for as long as onset stays deferred in its insured population, and stops paying when it does not. Nothing in any of the six public rulebooks could host that instrument today. Several private balance sheets could host it tomorrow, which is why this series keeps returning to insurers and large employers as the most plausible source of non-dilutive capital for this category in Asia-Pacific.

WHAT WOULD HAVE TO CHANGE

The demographic setting supplies the cruel symmetry. Japan's share of population aged 65 and over is approaching thirty percent. Korea crossed the twenty percent super-aged line in December 2024 and stood above 21 percent a year later. Super-aged systems are, by construction, financing the consequences of aging at colossal scale, and it is exactly that load that squeezes annual budgets hard enough to make long-horizon flexibility the first casualty. The systems that need deferral most are, by the same arithmetic, the least able to buy it. That is not a paradox to be marvelled at. It is a method problem, and methods can be amended. Four amendments would do it, and each already exists somewhere in the region in partial form.

First, an aggregation rule: a filing whose value is the sum of deferrals across several conditions needs the method to add, not average. Japan's weighted-mean treatment of multi-indication products proves that multi-stream arithmetic is administrable inside a real pricing system; the machinery needs a version that runs in the other direction. Second, a horizon rule: preventive claims assessed at full modelled horizon, with the discount rate set by explicit current policy rather than by a convention from 1990. Australia's own review has already published the defensible range. Third, a comparator convention for no-predecessor categories, with a domestic price-formation method that does not depend on importing a foreign price that does not exist. Korea's exemption track is the half-built precedent. Fourth, a payment instrument matched to the benefit's maturity: annual, outcomes-contingent, amortised across the deferral rather than scored whole against the launch-year budget. Taiwan's refund agreements and Korea's caps are the embryonic forms, and China's commercial list is the routing infrastructure such an instrument would travel through.

None of these requires new money. Each requires a method committee to decide, in advance of the first filing, what it would take to say yes, which is a cheaper and quieter act than any budget negotiation. Until one of the six does it, the title of this story remains a factual description. A drug that keeps five diseases away for three years each has, today, in every major payer system between Tokyo and Canberra, the same payer: nobody.

arcilla.fran@biopharmaapac.com

SOURCES AND METHOD

Payer system descriptions are drawn from each agency's own published guidance and official materials: Chuikyo and C2H materials on Japan's cost-effectiveness evaluation framework and its April 2019 incorporation into pricing; the Korean positive list literature and HIRA-linked deliberative record on thresholds, risk-sharing agreements and the 2015 pharmacoeconomic evaluation exemption; Taiwan National Health Insurance Administration and Center for Drug Evaluation materials, including the 42-day assessment standard and the September 2018 managed entry amendment; the Agency for Care Effectiveness Drug and Vaccine Evaluation Methods and Process Guide version 3.1 and the 2024 published review of the first six company-led submissions; the PBAC Guidelines base-case discount rate and the published record of the 2022 discount rate review; and National Healthcare Security Administration announcements for the 2025 National Reimbursement Drug List and the first Commercial Health Insurance Innovative Drug List of 7 December 2025, effective 1 January 2026. Demographic figures are from official national statistics as reported at the dates given. Discounted present values are computed at the stated rates over a thirty-year horizon. Where this story states that a method contains no provision, that statement rests on the absence of such provision from the cited guidance, not on inference from behaviour. No payer system is scored or ranked, and no market is benchmarked; regional benchmarking is the province of the APAC Bioeconomy Index. All facts were verified to 4 September 2026.